Imatinib in Patients With Desmoid Tumor and Chondrosarcoma
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Imatinib Mesylate is active in diseases -
such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the platelet-derived
growth factor (PDGF) both in its isoform alpha and beta